| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/BF00544017 |
| P698 | PubMed publication ID | 6617727 |
| P2093 | author name string | E Weber | |
| M Da Prada | |||
| A Stiehl | |||
| U Gundert-Remy | |||
| G Zürcher | |||
| R Hildebrandt | |||
| P2860 | cites work | Clinical pharmacokinetics of levodopa in parkinson's disease | Q28329436 |
| Levodopa pharmacokinetics. Alterations after benserazide, a decarboxylase inhibitor | Q39195776 | ||
| The clinical physiology of side effects in long-term L-DOPA therapy. | Q39875273 | ||
| Levodopa and decarboxylase inhibitors: a review of their clinical pharmacology and use in the treatment of parkinsonism | Q40575022 | ||
| Levodopa in Parkinsonism: Potentiation of Central Effects with a Peripheral Inhibitor | Q51107835 | ||
| Variability of L-Dopa Absorption in Man | Q54313520 | ||
| Active Transport of L-Dopa in the Intestine | Q59068223 | ||
| Dosage form design for improvement of bioavailability of levodopa II: bioavailability of marketed levodopa preparations in dogs and parkinsonian patients | Q64797296 | ||
| Systemic activity of orally administered L-dopa in the elderly Parkinson patient | Q64813435 | ||
| Metoclopramide, Gastric Emptying and L-Dopa Absorption | Q64869681 | ||
| L-dopa level in plasma, primary condition for the kinetic effect | Q64891561 | ||
| The role of the liver in the clearance ofl-dopa from plasma | Q66924030 | ||
| Radioenzymatic assay of femtomole concentrations of DOPA in tissues and body fluids | Q66927091 | ||
| Dosage form design for improvement of bioavailability of levodopa IV: Possible causes of low bioavailability of oral levodopa in dogs | Q70878989 | ||
| Plasma DOPA response to levodopa administration in man: Effects of a peripheral decarboxylase inhibitor | Q71783759 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 69-72 | |
| P577 | publication date | 1983-01-01 | |
| P1433 | published in | European Journal of Clinical Pharmacology | Q1376707 |
| P1476 | title | Intestinal absorption of levodopa in man | |
| P478 | volume | 25 |
| Q68499855 | Controlled-release levodopa/benserazide (Madopar HBS): clinical observations and levodopa and dopamine plasma concentrations in fluctuating parkinsonian patients |
| Q24544087 | Domperidone and levodopa in Parkinson's disease |
| Q60907407 | Gut bacterial tyrosine decarboxylases restrict levels of levodopa in the treatment of Parkinson's disease |
| Q48921343 | Improvement of L-dopa absorption by dipeptidyl derivation, utilizing peptide transporter PepT1. |
| Q41936454 | Pharmacokinetics of Levodopa before and after Gastrointestinal Resection in Parkinson's Disease |
| Q69597859 | Photoperiodic influence on the innervation of the ductus epididymidis and ductus deferens of the Djungarian hamster, Phodopus sungorus: electron-microscopic and biochemical results |
| Q47636343 | Sustained-release of levodopa: single dose study of a new formulation |
| Q43504961 | Synthesis of L-(+)-3-(3-hydroxy-4-pivaloyloxybenzyl)-2,5-diketomorpholine as potential prodrug of L-dopa. |
| Q69512834 | The absorption of piretanide from the gastro-intestinal tract is site-dependent |
| Q40214837 | The pharmacology of Parkinson's disease: basic aspects and recent advances |
Search more.